The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).
 
Thomas Powles
Consulting or Advisory Role - Exelixis; GlaxoSmithKline; Novartis
Research Funding - Exelixis; Genentech; GlaxoSmithKline; Novartis
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Bernard J. Escudier
Honoraria - Bayer; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Exelixis; GlaxoSmithKline; Novartis; Pfizer
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Seagen
 
Joanna Pikiel
No Relationships to Disclose
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma
 
Sun Young Rha
No Relationships to Disclose
 
Se Hoon Park
No Relationships to Disclose
 
Poul F. Geertsen
Research Funding - AVEO; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Marine Gross-Goupil
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Enrique Grande
No Relationships to Disclose
 
Cristina Suarez
No Relationships to Disclose
 
Alan M Arroyo
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Mark Dean
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Daniel George
Honoraria - Bayer; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Novartis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Viamet Pharmaceuticals (Inst)
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)